The groundbreaking success of the copyright undeniably revolutionized the drug landscape, but betting in companies primarily reliant on off-patent versions presents a challenging picture. While early returns were significant, the cessation of patents and the rise of cheaper alternatives have eroded sales. Therefore, a thorough analysis of ongoing i